Actively Recruiting
The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife
Led by Pengfei Qiu · Updated on 2025-03-30
90
Participants Needed
1
Research Sites
142 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.
CONDITIONS
Official Title
The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical and laboratory diagnosis of moderate to severe allergic rhinitis
- Aged 18 to 75 years, any gender or ethnicity
- No antihistamines or nasal steroids taken within 1 month before enrollment
- Voluntary participation with signed informed consent
- Able to attend outpatient treatment for 4 weeks
You will not qualify if you...
- Atrophic rhinitis, hypertrophic rhinitis, vasomotor rhinitis, acute or chronic sinusitis, nasal polyps, severe septal deviation, eosinophilia non-allergic rhinitis
- Other allergic diseases causing nasal symptoms such as asthma, urticaria, or colds
- Serious cardiovascular, cerebrovascular, liver, kidney, or blood system diseases
- Pregnant or breastfeeding women
- Psychiatric patients
- Patients with malignant tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Hospital
Hangzhou, Zhejiang, China, 310030
Actively Recruiting
Research Team
P
Pengfei Qiu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here